Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 310-326 |
| Number of pages | 17 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 1 Dec 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study. / Weaver, Nick A.; Zhao, Lei; Biesbroek, J. Matthijs et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 01.12.2019, p. 310-326.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study
AU - Weaver, Nick A.
AU - Zhao, Lei
AU - Biesbroek, J. Matthijs
AU - Kuijf, Hugo J.
AU - Aben, Hugo P.
AU - Bae, Hee-Joon
AU - Caballero, Miguel Á.A.
AU - Chappell, Francesca M.
AU - Chen, Christopher P. L. H.
AU - Dichgans, Martin
AU - Duering, Marco
AU - Georgakis, Marios K.
AU - van der Giessen, Ruben S.
AU - Gyanwali, Bibek
AU - Hamilton, Olivia K. L.
AU - Hilal, Saima
AU - vom Hofe, Elise M.
AU - de Kort, Paul L. M.
AU - Koudstaal, Peter J.
AU - Lam, Bonnie Y. K.
AU - Lim, Jae-Sung
AU - Makin, Stephen D. J.
AU - Mok, Vincent C. T.
AU - Shi, Lin
AU - Valdés Hernández, Maria C.
AU - Venketasubramanian, Narayanaswamy
AU - Wardlaw, Joanna M.
AU - Wollenweber, Frank A.
AU - Wong, Adrian
AU - Xin, Xu
AU - DeCarli, C.
AU - Fletcher, E. A.
AU - Maillard, P.
AU - Barnes, J.
AU - Sudre, C. H.
AU - Schott, J. M.
AU - Ikram, M. A.
AU - Papma, J. M.
AU - Steketee, R. M. E.
AU - Vernooij, M. W.
AU - Bordet, R.
AU - Lopes, R.
AU - Huang, C. W.
AU - Chaturvedi, N.
AU - Barkhof, F.
AU - van der Flier, W. M.
AU - Meta VCI Map consortium
AU - Calgary Normative Study group
AU - Framingham Heart Study group
AU - The Dutch Parelsnoer Institute – Neurodegenerative diseases group
AU - TABASCO group
N1 - Funding Information: N.A.W. was the study coordinator, contributed to the design of the consortium and the pilot study, analyzed the data, and wrote the manuscript. L.Z. was a coinvestigator, analyzed the data, and contributed to the writing of the manuscript. J.M.B. and H.J.K. were coinvestigators, contributed to the design of the consortium and the pilot study, and contributed to the writing of the manuscript. G.J.B. was the leading investigator and chairman of the consortium, conceived and designed the consortium and the pilot study, and wrote the manuscript. H.J.B., C.P.L.H.C., M.D., R.S.G., O.K.L.H., S.H., P.L.M.K., B.Y.K.L., J.S.L., V.C.T.M., and J.M.W. were members of the Meta VCI Map Steering Committee, who contributed to the design of the consortium and pilot study, and reviewed the content of the draft and final manuscript. Other listed authors contributed to the pilot study and/or were involved in data acquisition and analysis of the cohorts included in the pilot study. Authors included under the banner of “Meta VCI Map consortium” are representatives from the Meta VCI Map member groups, who provided information on their respective cohorts for presentation in the overview table, and reviewed and approved the final version of the article. Meta VCI Map consortium—collaborating authors: ADNI (Team UC Davis) and UC Davis ADC Diversity Cohort: C. DeCarli, University of California at Davis; E.A. Fletcher, University of California at Davis; P. Maillard, University of California at Davis. ADNI (Team UCL), PRE-MCI, and YOAD: J. Barnes, University College London (UCL) Queen Square Institute of Neurology; C.H. Sudre, School of Biomedical Engineering and Imaging Sciences King's College, London Dementia Research Centre Institute of Neurology–UCL, and Department of Medical Physics and Biomedical Engineering–UCL; J.M. Schott, UCL Queen Square Institute of Neurology. Alzheimer Center Erasmus MC and Rotterdam Study: M.A. Ikram, Erasmus MC—University Medical Center Rotterdam; J.M. Papma, Erasmus MC—University Medical Center Rotterdam; R.M.E. Steketee, Erasmus MC—University Medical Center Rotterdam; M.W. Vernooij, Erasmus MC—University Medical Center Rotterdam. BIOSTROKE and STROKDEM: R. Bordet, University of Lille; R. Lopes, University of Lille. CAC-KCGMH and Kaohsiung Chang Gung Memorial Hospital stroke cohort: C.-W. Huang, Chang Gung Memorial Hospital Taiwan. Calgary Normative Study, FAVR and Brain IMPACT: R. Frayne, University of Calgary; C.R. McCreary, University of Calgary; E.E. Smith, University of Calgary; Calgary Normative Study group (list in Appendix ). CASPER, Cognitive function after lacunar stroke MUMC study, and Blood-brain barrier in cerebral small vessel disease cohort: W. Backes, Maastricht UMC+; S. Köhler, Maastricht UMC+; R.J. van Oostenbrugge, Maastricht UMC+; J. Staals, Maastricht UMC+; F. Verhey, Maastricht UMC+. COAST, Harmonization and EDIS: C.Y. Cheng, Singapore National Eye Centre. CogFAST-UK: R.N. Kalaria, Newcastle University Institute of Neuroscience (more in Appendix ). CROMIS-2: D. Werring, UCL Institute of Neurology. Linkou Chang Gung Memorial Hospital stroke cohort: J.L. Hsu, Chang-Gung University and Taipei Medical University; K.-L. Huang, Chang-Gung University. DANTE and PROSPER: J. van der Grond, Leiden University Medical Center; J.W. Jukema, Leiden University Medical Center; R.C. van der Mast, Leiden University Medical Center. De Hoogstraat Rehabilitation: T.C.W. Nijboer, Center of Excellence in Rehabilitation Medicine Utrecht, UMC Utrecht & De Hoogstraat Rehabilitation. Framingham Heart Study: Framingham Heart Study group. Hallym VCI cohort: K.-H. Yu, Hallym University. Parelsnoer Neurodegenerative diseases: The Dutch Parelsnoer Institute—neurodegenerative diseases group (list in Appendix ). PRODEM-Austria and ASPS: R. Schmidt, Department of Neurology, Division of Neurogeriatrics, Medical University of Graz, Austria; L. Pirpamer, Department of Neurology, Division of Neurogeriatrics, Medical University of Graz, Austria. RISE1, RISE2, and RISE3: B.J. MacIntosh, Sunnybrook Research Institute Toronto, University of Toronto, and Heart and Stroke Foundation Canadian Partnership for Stroke Recovery; A.D. Robertson, Sunnybrook Research Institute Toronto, Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, and University of Waterloo. RUN DMC: F.-E. de Leeuw, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour; A.M. Tuladhar, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behavior. SABRE: N. Chaturvedi, UCL Institute of Cardiovascular Science; T. Tillin, UCL Institute of Cardiovascular Science. Sydney MAS: H. Brodaty, UNSW Sydney; P. Sachdev, UNSW Sydney. TABASCO: TABASCO group (list in Appendix ). TRACE-VCI: F. Barkhof, Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC; W.M. van der Flier, Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC. USCOG: L.J. Kappelle, University Medical Center Utrecht. The Meta VCI Map consortium is supported by Vici Grant 918.16.616 from ZonMw , The Netherlands, Organisation for Health Research and Development, to G.J.B. Additional grant support pilot study cohorts: The CODECS study is supported by a grant from Stichting Coolsingel , the Netherlands. Funding for the PROCRAS study was obtained through ZonMw as part of the ‘TopZorg’ project in 2015 (grant # 842003011 ). The CU-STRIDE study was funded by the Health and Health Services Research Fund ( 0708041 ) of the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region . The CU-RISK study was funded by General Research Fund (grant number GRF CUHK 471911 ), the National Key Research and Development Program of China (grant number 2016YFC1300600), and the Lui Che Woo Institute of Innovative Medicine , and Therese Pei Fong Chow Research Center for Prevention of Dementia (in memory of Donald H. K. Chow). The Mild Stroke Study 2 was funded by the Wellcome Trust ( WT088134/Z/09/A ), the Row Fogo Charitable Trust and Chest Heart & Stroke Scotland (long-term follow-up, ref no: Res14/A157). J.M.W. is supported by the Fondation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small Vessel Disease (ref no. 16 CVD 05) and the UK Dementia Research Institute at The University of Edinburgh . O.K.L.H. is supported by the College of Medicine and Veterinary Medicine at the University of Edinburgh and the Wellcome Trust . Publisher Copyright: © 2019 The Authors Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Introduction: The Meta VCI Map consortium performs meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping. Integration of data from different cohorts will increase sample sizes, to improve brain lesion coverage and support comprehensive lesion-symptom mapping studies. Methods: Cohorts with available imaging on white matter hyperintensities or infarcts and cognitive testing were invited. We performed a pilot study to test the feasibility of multicenter data processing and analysis and determine the benefits to lesion coverage. Results: Forty-seven groups have joined Meta VCI Map (stroke n = 7800 patients; memory clinic n = 4900; population-based n = 14,400). The pilot study (six ischemic stroke cohorts, n = 878) demonstrated feasibility of multicenter data integration (computed tomography/magnetic resonance imaging) and achieved marked improvement of lesion coverage. Discussion: Meta VCI Map will provide new insights into the relevance of vascular lesion location for cognitive dysfunction. After the successful pilot study, further projects are being prepared. Other investigators are welcome to join.
AB - Introduction: The Meta VCI Map consortium performs meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping. Integration of data from different cohorts will increase sample sizes, to improve brain lesion coverage and support comprehensive lesion-symptom mapping studies. Methods: Cohorts with available imaging on white matter hyperintensities or infarcts and cognitive testing were invited. We performed a pilot study to test the feasibility of multicenter data processing and analysis and determine the benefits to lesion coverage. Results: Forty-seven groups have joined Meta VCI Map (stroke n = 7800 patients; memory clinic n = 4900; population-based n = 14,400). The pilot study (six ischemic stroke cohorts, n = 878) demonstrated feasibility of multicenter data integration (computed tomography/magnetic resonance imaging) and achieved marked improvement of lesion coverage. Discussion: Meta VCI Map will provide new insights into the relevance of vascular lesion location for cognitive dysfunction. After the successful pilot study, further projects are being prepared. Other investigators are welcome to join.
KW - Cerebrovascular disease
KW - Consortium
KW - Data harmonization
KW - Lesion location
KW - Lesion-symptom mapping
KW - Small vessel disease
KW - Stroke
KW - Support vector regression
KW - Vascular cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85064191398&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2019.02.007
DO - 10.1016/j.dadm.2019.02.007
M3 - Article
C2 - 31011619
VL - 11
SP - 310
EP - 326
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
SN - 2352-8729
ER -